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Summary. Although live-attenuated vaccines have been used for some time to
control clinical symptoms of the porcine reproductive and respiratory syndrome
(PRRS), the molecular bases for the attenuated phenotype remain unclear. We
had previously determined the genomic sequence of the pathogenic PRRSV
16244B. Limited comparisons of the structural protein coding sequence of an
attenuated vaccine strain have shown 98% homology to the pathogenic 16244B.
Here we have confirmed the attenuated phenotype and determined the genomic
sequence of that attenuated PRRSV vaccine and compared it to its parental VR-
2332 and the 16244B strains. The attenuated vaccine sequence was colinear
with that of the strain 16244B sequence containing no gaps and 212 substitu-
tions over 15,374 determined nucleotide sequence. We identified nine amino acid
changes distributed in Nsp1b, Nsp2, Nsp10, ORF2, ORF3, ORF5 and ORF6.
These changes may provide the molecular bases for the observed attenuated
phenotype.
Introduction
Porcine reproductive and respiratory syndrome (PRRS), is a devastating viral
disease characterized by reproductive failure in sows, pre-weaning mortality and
respiratory illness in piglets [1, 24]. The causative agent, PRRSV [30], belongs
to the Arteriviridae family together with lactate dehydrogenase-elevating virus
The GenBank accession number for the PRRSV modified live vaccine (complete
genome) reported in this paper is AF159149.
†Deceased
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(LDV) of mice, equine arteritis virus (EAV) and simian haemorrhagic fever virus
(SHFV) [3].
Inactivated and live-attenuated vaccines have been developed to control the
clinical symptoms of PRRS [5, 10, 22, 26]. Although attenuated PRRSV vaccines
have been in use since 1994, the molecular basis for their reduced pathogenicity
remains unclear. Two sequencing studies of the structural protein coding region
of the attenuated PRRSV vaccine that has been in use the longest, have been
conducted [15, 33]. From these studies, two nucleotides changes in ORF5 and
ORF6 respectively were described as possibly influencing the PRRSV virulence
[15]. However, no data have been reported on molecular changes which may
have occurred elsewhere in the entire genome during the attenuation process and
probably involved in loss of PRRSV virulence.
We have previously determined the genomic sequence of the North American
pathogenic 16244B PRRSV isolate [2]. Preliminary analysis conducted in our
laboratory, of the 30 end of the 16244B strain and the attenuated PRRSV vaccine
strain referenced above revealed a high genetic identity of 98% (unpublished data).
Furthermore the sequence comparison of PRRSV 16244B and the parental strain
of the vaccine VR-2332 [19] revealed high identity (unpublished data). Taken
together, these observations suggest that as previously reported in other PRRSV
field isolates the PRRSV 16244B could be one example of the virulent derivatives
of the attenuated PRRSV vaccine that have been recently reported to occur in the
field [17]. Therefore, the pathogenic potential of 16244B becomes of interest to
characterize. Furthermore, in order to determine which changes may actually be
responsible and which not for the reduction of PRRSV virulence we confirmed
the in vivo phenotype and determined the nearly entire genomic sequence of
the attenuated vaccine strain and compared it to that of its parental VR-2332
(a bonafide pathogenic strain [6]) and the closely related PRRSV 16244B field
isolate.
This study showed that nine amino acid changes distributed in Nsp1b, Nsp2,
Nsp10, ORF2, ORF3, ORF5, and ORF6 might be responsible for the attenuated
PRRSV phenotype.
Materials and methods
Virus, cells and RNA isolation
We used the commercially available modified live PRRSV vaccine RespPRRS /Repro (NOBL
Laboratories, Inc.), a cell passaged attenuated strain derived from the pathogenic PRRSV
field isolate VR-2332 [4]. The vaccine strain was derived by twenty-five passages in mon-
key kidney cell line MA-104 at 35 C−37 C, followed by twelve passages at 31 C in
the same cell line. The commercial product (Serial #JA-441A-203) obtained from a
licensed vaccine dealer, was reconstituted and used to inoculate monolayers of MARC-
145 cells, a subclone of the monkey kidney cell line MA-104 [12]. After two cell cul-
ture passages, supernatants containing infectious virus were collected, titered in monolayers
of MARC-145 cells and stored for further animal inoculations. The total RNA was ex-
tracted from the infected cell monolayers using TRIzol (GibcoBRL) following manufacturer’s
protocol.
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The pathogenic PRRSV strain 16244B isolated in Nebraska, U.S.A., in 1997 has already
been described [2]. The 16244B virus was replicated in monolayers of MARC-145 cells. After
two cell culture passages, the infected monolayers were frozen and thawed and clarified by
low speed centrifugation. Viral suspensions were titered in monolayers of MARC-145 cells
and stored for further animal inoculation.
Animal inoculations
Two groups of four PRRSV seronegative pregnant sows (Landrace breed) each were inocu-
lated at 90 days of gestation. One group received 104.7 CCID50%/2 ml of vaccine virus and
the second group received 105.0 CCID50%/2 ml of 16244B PRRSV strain. All the animals
received one ml inoculum in each nostril. Animals were kept in strict isolation in separate
rooms and observed daily. Two markers for viral pathogenicity were observed, 1) the in-
duction of abortion and 2) the rate of piglet survival at 10 days after farrowing. The results
of farrowing performance and piglets health were recorded throughout a two week period.
The general appearance, signs of respiratory distress, diarrhea and overall body conditions
were monitored during this period. Serum samples were collected from sows at 7 days after
farrowing for PRRSV antibody detection. Lung and spleen tissue, lymph nodes and serum
samples were taken, from piglets born alive and from others, shortly after death, for viral
isolation in monolayers of MARC-145 cells. Viral identification was performed in formalin
fixed and paraffin-embedded tissues from the same piglets using immuno-histochemistry
(IHC) as described by Sur et al. [27].
The pathogenicity of PRRSV VR-2332 in pregnant sows has been previously reported
[6].
Table 1. Oligonucleotides used for amplification of PRRSV vaccine strain
Code Sequence (50–30) Locationa
RA-1F TGCCTCGGCATTTGTATTGTCAG 24–46
RA-3R CTTGCAGCCTCCGCTGTAGGTACT 1100–1123
RA-8R CGAACGATCGGAATCGCCAG 1907–1926
RA-9F CTGCCTGCCTTGACTGGCT 1832–1850
RA-12R ACTGCCGCCGCCGAACTCAATCTT 3003–3026
RA-11F ACCGCCGTGCTCTCCAAGTTGGAA 2395–2418
RA-16R CAATGCCAAGCCTAAGCA 4304–4321
RA-17F CCTGTTCGCAGCCTTGTTGTG 4213–4233
RA-22R CGGGCAATCAGCTATAG 5813–5830
RA-21F TCGGAGGCATGGCTCATAGG 5198–5218
RA-26R AGCGAGGGCACCAGTCAGAGACTC 6784–6807
RA-27F CTTGTTGGCGATGGAGTGTTCTCT 6685–6708
RA-30R CATCGATCGGTCTCGCAACCGGGT 7861–7884
RA-31F CAGCGGCTTGACCCGCTGTGGTCG 7706–7729
RA-37F TGGTGATCTATGCACAGCATATGG 9085–9108
RA-42R GGAATCAATAGTGATGGCGTC 10596–10616
RA-43F CTGTCAGGTATGGGCAGG 10546–10563
RA-48R GGCAGGGCGCGTACGGAG 12249–12266
aLocations are from the sequence of PRRSV 16244B strain (GenBank
Accession No. AFO46869)
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RT-PCR, PCR and cDNA cloning
Viral cDNAs were synthesized by RT-PCR using random hexanucleotide primers and
SuperScript II reverse transcriptase (GibcoBRL) following the supplier’s instructions. The
resulting cDNA was used as template in the PCR. The PCR was performed with PRRSV-
specific primers designed from the sequence of the North American PRRSV 16244B strain [2]
(Table 1). PCR products were cloned into the pCR2.1-TOPO vector (Invitrogen) following
manufacturer’s instruction.
Sequence analysis
RT-PCR products and cloned cDNA inserts were sequenced by dideoxynucleotide chain-
termination method [23]. Sequencing reactions were prepared with the BigDye Terminator
Cycle Sequencing kit (Perkin Elmer). Sequences were determined with an ABI PRISM
377 automated DNA sequencer and an ABI PRISM 3700 DNA analyzer. The ABI sequence
sequence software version 3.3 was used for lance tracking and trace extraction. Further cDNA
sequencing, genome assembling and computer analysis was done as described in Allende et
al. [2]. The consensus sequence had at least fourfold redundancy at each nucleotide position
in both directions, with an average ten-fold redundancy.
Sequence comparison to PRRSV VR-2332 was done using the GenBank data base
Accession No. PRU87392 [19].
Results
Animal inoculations
The phenotypes of both strains (RespPRRS/Repro and 16244B) were different as
defined by the two markers of viral pathogenicity (Table 2). Animals incoculated
with PRRSV 16244B farrowed an average of six live piglets and the rate of
survival at 10 days after farrowing was of 29%. Similar results were reported in
sows inoculated with the parent of the vaccine PRRSV VR-2332 [6] (Table 2). In
contrast animals inoculated with the vaccine strain had an average of 13 piglets
born alive and the rate of survival at 10 days post farrowing was of 94%. The piglets
Table 2. Comparison of the phenotype of the PRRSV vaccine, 16244B and VR-2332 strains
by intranasal inoculation of sows at 90 days of gestation
Vaccine 16244B VR-2332a
Sow ID: A B C D E F G H 7 8 9
Days to
farrowing 113 115 115 113 106 114 115 117 P D 0.55b 112 114 110
Piglet status:
-born alive 14 13 13 12 5 8 4 7 P D 0.02 5 8 5
-dead 1 1 1 1 4 4 2 2 P D 0.01 4 3 2
-mummified 1 − − − 2 − 3 1 P D 0.01 4 3 2
Piglet survival
at 10 days: 12 12 12 12 0 1 3 3 P D 0.02
aChristianson et al. [6]
bMann-Whitney U test for median comparison
PRRSV attenuation phenotype 1153
born alive in the group inoculated with PRRSV 16244B looked weak, unthrifty
and feverish. The piglets born from the group inoculated with the attenuated
vaccine strain appeared normal. Gross pathology and histopathology studies were
performed in all the piglets that died shortly after birth. The results indicated
that some piglets in the PRRSV 16244B-inoculated group had mild interstitial
pneumonia and a mild vasculitis involving branches of the pulmonary artery was
noted in one of these piglets. Infectious virus was isolated from serum samples
of these piglets which were also PRRSV positive by IHC performed on samples
of their lung tissues. In the PRRSV vaccine-inoculated group, perinatal mortality
was unrelated to PRRSV infection (i.e. traumatic as a result of being lied on by
the dam). The gross pathology examination of these piglets was normal. Lung
tissue samples from these piglets were PRRSV negative by IHC. Infectious virus
was isolated from a pool of sera taken at 7 days post farrowing from the healthy
piglets born from sow A of the vaccinated group. Attempts to recover infectious
virus from the other litters in the vaccinated group were negative. Nevertheless,
the median time of gestation to farrowing was similar in both groups of sows.
All sows in the experiment except for sow D from the vaccine-inoculated group,
developed PRRSV antibodies as indicated by the ELISA positive results. The lack
of seroconversion upon intranasal inoculation in one animal coincides with our
previous observations that indicate that this PRRSV modified live vaccine, when
given by the recommended route, can also fail to induce antibodies as detected
by ELISA [20].
Genome sequence analysis
The determined consensus sequence of the vaccine genome was 15,374 bases
long comprising the entire coding region, 30 non-coding region (NCR) and 165
nucleotides of the 50 NCR. The consensus sequence of the vaccine PRRSV strain
was more than 99% identical to and colinear with the sequence of the North Amer-
ican PRRSV 16244B [2] with 212 nucleotide substitutions and neither deletions
nor insertions. From these nucleotide substitutions 20 were transversions (T>A;
A>T; C>G; T>G; G>T or A>C). In 196 out of these 212 positions the vaccine
was identical to its parental strain [19]. Analysis of the comparison indicated
that the vaccine strain had 29 non-conservative and 46 conservative amino acid
changes over the entire coding region. The observed non-conservative changes
were located in ORF1a (23 changes), ORF1b (2 changes), ORF2 (1 change),
ORF3 (2 changes) and ORF5 (1 change).
Although the only cleavage product of EAV ORF1ab polyprotein that has
been confirmed for PRRSV is Nsp1 (Nsp1a and Nsp1b), here we will adopt the
nomenclature proposed for EAV ORF1ab polyprotein processing products and
name the putative PRRSV non structural proteins Nsp1 to 12 [24, 28, 29].
50 NCR
We determined 165 bases from the predicted 189 base length of the 50 NCR.
The 50 NCR of the vaccine strain had only one nucleotide transition (C>T) at
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position 103 when compared to PRRSV 16244B but was identical to the parental
strain VR-2332 at this position [19]. The consensus ORF1a start sequence 50-
UAACCAUG-30 [2, 18, 19] was conserved in the vaccine strain.
Analysis of the ORF1a
From the total of 212 nucleotides substitutions observed over the entire vaccine
sequence, 117 were located in ORF1a. However the polyprotein encoded by the
vaccine strain was 2503 residues long and 97.9% identical to 16244B isolate [2]
All four protease domains, their six putative catalytic residues and cleavage sites
were conserved in the vaccine strain sequence. A total of 29 conservative and 23
non-conservative amino acid changes were identified in the ORF1a polyprotein
(Table 3).
The predicted non-conservative amino acid changes were concentrated in the
cleavage products Nsp1b and Nsp2, evenly distributed on both cleavage products
and not associated with any particular catalytic or cleavage site. The vaccine
strain’s Nsp1b had 5 non-conservative amino acid changes over a total length of
Table 3. Nucleotides and amino acids differences found between vaccine and
16244B strains of PRRSV
No. of changes/total for each region (%)
Genome region amino acid
nucleotide conservative non-conservative
50 NCR 1/165(0.6) – –
ORF1a:
Nsp1a 4/498 (0.8) 2/166 (1.2) 0/166 (0)
Nsp1b 16/651 (2.4) 3/217 (1.4) 5/217 (2.3)
Nsp2 61/2, 940 (2.1) 16/980 (1.6) 17/980 (1.7)
Nsp3 16/1, 338 (1.2) 3/446 (0.7) 0/446 (0)
Nsp4 4/612 (0.6) 2/204 (1.0) 0/204 (0)
Nsp5–8 15/1, 335 (1.1) 3/445 (0.7) 1/445 (0.2)
Junction 2/71 (2.8) – –
ORF1b:
Nsp9 25/1, 938 (1.3) 2/646 (0.3) 2/646 (0.3)
Nsp10 16/1, 323 (1.2) 2/441 (0.4) 0/441 (0)
Nsp11 3/672 (0.4) 1/223 (0.4) 0/223 (0)
Nsp12 6/456 (1.3) 2/152 (1.3) 0/152 (0)
ORF2 10/768 (1.3) 1/256 (0.4) 1/256 (0.4)
ORF3 10/762 (0.8) 3/254 (1.2) 2/254 (0.8)
ORF4 3/534 (0.6) 1/178 (0.6) 0/178 (0)
ORF5 15/600 (2.5) 3/200 (1.5) 1/200 (0.5)
ORF6 8/522 (1.5) 2/174 (1.1) 0/174 (0)
ORF7 1/369 (0.3) 0/123 (0) 0/123 (0)
30 NCR 0/150 (0) – –
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Table 4. Nucleotides and amino acids differences found between PRRSV
vaccine and its parental strain (PRRSV VR-2332)a
No. of changes/total for each region (%)
Genome amino acid
region
nucleotide conservative non-conservative
50 NCR 1/165(0.6) – –
ORF1a:
Nsp1a 1/498(0.2) 0/166(0) 0/166(0)
Nsp1b 2/651(0.3) 1/217(0.4) 1/217(0.4)
Nsp2 4/2,940(0.13) 2/980(0.2) 1/980(0.1)
NSp3 2/1,338(0.15) 1/446(0.2) 0/446(0)
Nsp4 0/612(0) 0/204(0) 0/204(0)
Nsp5–8 2/1,335(0.15) 0/445(0) 1/445(0.2)
Junction 0/71(0) – –
ORF1b:
Nsp9 0/1,938(0) 0/646(0) 0/646(0)
Nsp10 6/1, 323(0.45) 1/441(0) 2/441(0.4)
Nsp11 5/672(0.4) 3/224(1.3) 1/224(0.4)
Nsp12 2/456(0.4) 0/152(0) 0/152(0)
ORF2 3/768(0.39) 2/256(0.8) 0/256(0)
ORF3 5/762(0.65) 2/254(0.8) 1/254(0.4)
ORF4 1/534(0.18) 1/178(0.6) 0/178(0)
ORF5 2/600(0.3) 1/200(0.5) 1/200(0.5)
ORF6 3/522(0.57) 1/174(0.6) 1/174(0.6)
ORF7 0/369(0) 0/123(0) 0/123(0)
30 NCR 0/150(0) – –
aNelsen et al. [19]; GenBank Accession No. PRU87392
217 residues and the Nsp2 had 17 non-conservative changes over a total length of
980 amino acids. The remaining cleavage products Nsp1a and Nsp3 to Nsp8 were
very similar to 16244B with a total of 11 amino acid mutations (Table 3). When
compared to its parental VR-2332 strain, the vaccine ORF1a had only 6 amino
acid mutations (Table 5). However, the vaccine strain was identical to the 16244B
strain at 3 of these positions (Table 5), thus suggesting that only 3 ORF1a residues
identified as F331, F668 and K952 could be considered as putative candidates for
attenuation PRRSV phenotype. From them, the F331 and F668 are non-conservative
substitutions which may represent a stronger change in the composition of the
putative proteins (Nsp1b and Nsp2).
The ORF1a-ORF1b junction region
There were two nucleotide changes in this region. The G7687 A in the stem 1
of the predicted vaccine RNA pseudoknot structure giving rise to a slightly
stronger structure than 16244B (−82.5 KJ/mol) and the G7724 A in the loop region
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Table 5. Amino acids changes between PRRSV vaccine
strain and VR-2332 and its comparison to 16244B
PRRSV strain
Genome region Vaccine VR-2332a 16244B
ORF1a:
Nsp1a – – –
Nsp1b F331 S331 S331
Nsp2 F668 S668 S668
N951 D951 E951
K952 E952 E952
Nsp3 A1498 S1498 A1498
Nsp4 – – –
Nsp5–8 L2162 P2162 L2162
ORF1b:
Nsp9 – – –
Nsp10 E760 G760 E760
H952 Y952 Y952
R1042 C1042 R1042
Nsp11 T1126 S1126 T1126
E1181 G1181 E1181
L1184 V1184 L1184
A1217 G1217 A1217
Nsp12 – – –
ORF2 F10 L10 L10
S122 A122 S122
ORF3 E83 G83 G83
V94 I94 V94
S106 G106 S106
ORF4 G43 S43 G43
ORF5 Q13 R13 R13
G151 R151 R151
ORF6 E16 Q16 Q16
G121 R121 G121
ORF7 – – –
aNelsen et al. [19]; GenBank Accession No. PRU87392
(Table 3). The vaccine strain was identical to its parental strain at these positions
[19] (Table 4).
Analysis of ORF1b
Fifty nucleotide substitutions out of the 212 observed over the determined se-
quence were located in ORF1b. However the ORF1b of the vaccine strain was
99.4% identical to 16244B and only 9 amino acid substitutions over the 1463
residues were present (Table 3). All the Nsp9 to Nsp12 domains and motifs and
its cleavage sites [2, 19, 24] were conserved in the vaccine strain.
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The comparison of the vaccine strain with the parental VR-2332 strain re-
vealed seven amino acid substitutions (Table 5). Nevertheless the vaccine was
identical to the pathogenic strain 16244B at six of this positions. The conserva-
tive substitution Y952H was the only one unique to the vaccine strain in ORF1b
(Table 5) and was not related to a particular cleavage or catalytic site of the
polyprotein.
Analysis of ORF2 to 7
Forty-four nucleotide substitutions were present over the ORF2 to 7 sequence
(three of them were located in overlapping regions between two ORFs). The vac-
cine strain had a total of 14 amino acid mutations in this region being 4 of them
non-conservative substitutions. The residue changes at positions L10F (ORF2);
G83E (ORF3); R13Q and R151G (ORF5) and (Q16E (ORF6) were unique to the
vaccine strain but absent from its parental strain sequence (Table 5). The changes
in ORFs 5 and 6 were observed also by Madsen et al. [15]. Although the change
G83 E (ORF3) was absent from all the North American PRRSV isolates analyzed
[11, 16] it was present in three pathogenic field isolates from Denmark from pigs
putatively infected with the vaccine strain [15]. Analysis of the sequence of an-
other highly pathogenic PRRSV isolate collected in Iowa in 1997 (unpublished
data from this laboratory, strain obtained from NVSL, USDA/APHIS, Ames, IA,
USA) indicated similarity to PRRSV 16244B at positions R13 and Q16 which sug-
gest that changes at these positions may participate in attenuation. The mutation
identified in ORF2 was not observed in the vaccine sequence reported by Medsen
et al. [15]. There is not much information on the function of PRRSV gp2 but the
substitution of a L by a F would change the shape of this region of the putative
protein which could be enough to interfere with it function. We did not find any of
the amino acid changes described by Yang et al. [33] in the ORF2 to 7 sequence
of the vaccine strain.
30 NCR
The 30 NCR from the vaccine strain was identical to the 16244B strain [2] and to
the VR-2332 strain [33].
Discussion
Here we have confirmed the avirulent phenotype for pregnant female swine and
determined the genomic sequence of an attenuated PRRSV vaccine and com-
pared them to those of the parental PRRSV VR-2332 and the pathogenic PRRSV
16244B. Christianson et al. [6] had previously confirmed that the VR-2332 was
fully pathogenic when inoculated in sows at 90 days of gestation. Here we ob-
tained similar results with the closely related pathogenic PRRSV 16244B field
isolate. Statistically significant differences were observed in the virulence of these
strains compared to the attenuated vaccine strain as shown in Table 2. The vac-
cine strain failed to induce abortions and the rate of piglet survival at 10 days post
farrowing was of 94% compared to 29% for isolate 16244B.
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The vaccine genome sequence was colinear to the VR-2332 and the16244B
strains and there were no insertions or deletions. However, we identified five
amino acid mutations in the structural and four amino acid mutations in the non-
structural proteins coding region respectively that might be responsible for the
attenuated phenotype.
The structural glycoprotein gp5 encoded by ORF5 had two amino acid muta-
tions at positions R13Q and R151G that were unique for the vaccine strain. The Q13
is a conservative mutation and is located in the putative signal peptide sequence
of the gp5, which is removed after translation. This mutation would change the
net charge of the signal peptide probably influencing its function and interfering
with the transport of gp5 to the membrane of the endoplasmic reticulum. The
G151 change is located in the hydrophilic portion of the glycoprotein. It has been
suggested that G151 identifies the vaccine strain and could be one of the many
mutations involved in PRRSV attenuation [31]. Since gp5 is probably involved
in binding to cellular receptors and contains the major epitopes for inducing both
humoral and cellular immune responses [21] is then plausible that the observed
change could alter tissue tropism thus contributing to the attenuated phenotype. A
single amino acid change in the rabies virus glycoprotein [9] and in the poliovirus
Sabin type3 VP3 [32] is sufficient for the acquisition of an attenuated phenotype.
The protein encoded by ORF3 (gp3) had one unique mutation G83E which was
absent from other North American PRRSV isolates [11, 16]. The change may in-
crease the hydrophilicity of that region of the gp3 possibly affecting the function
of the protein that has not yet been determined in PRRSV. However the G83E
change was also described in three pathogenic Danish isolates from animals sus-
pected to be infected with the vaccine virus [15]. This data suggest that E83 would
be not likely involved in attenuation. Madsen et al. [15] reported the conservative
amino acid substitution E16 Q (ORF6) as possibly influencing virus virulence.
We have found the same amino acid substitution in ORF6 of the vaccine and we
agree with Madsen et al. [15] that changes at this position could possibly alter
the heterodimer (gp5/M) complex formation therefore influencing virus/host or
virus/cell interactions. A conservative amino acid substitution was observed in
the translation product of PRRSV vaccine ORF2. The function of the PRRSV
ORF2 is still unknown. However it has been recently described a novel ORF2a
gene in the arterivirus EAV and both ORF2a and ORF2b protein products are
required for the production of infectious EAV particles [25]. If PRRSV ORF2
has similar biological functions than EAV ORF2a and ORF2b, then it is plausible
to consider that mutations in this ORF could contribute to the PRRSV attenuation
phenotype.
Changes in residues of the non-structural proteins encoded by the replicase
gene have been reported to attenuate the phenotype of the coronavirus MHV-
A59 [13]. Here Nsp1b had a change S331F that was located 8 residues from
the catalytic site. The probable conformational change caused by this mutation
may be sufficient to alter the efficiency of the proteolytic cleavage, thus result-
ing in an attenuated phenotype. Two amino acid mutations unique to the vac-
cine strain were identified in Nsp2. Nsp2 has been suggested to be involved in
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species-specific functions [7]. No biological function has yet been identified for
this protein in PRRSV but the finding that it contained the majority of the amino
acids mutations is consistent with the suggested involvement in host range. It
is likely that during the attenuation process through adaptation to MA-104 cell
line several mutations took place in the Nsp2 portion of the ORF1a. Thus the
attenuated phenotype could be the consequence of the vaccine strain adaptation
to MA-104 cell line. However, it has been reported that the EAV Nsp2 acts as a
cofactor for the NSP4 protease [29] and its presence was necessary for the ma-
jor EAV ORF1ab proteolytic pathway [29]. It is then plausible to consider that
PRRSV Nsp2 could also be required as a cofactor for PRRSV Nsp4 protease. The
observed mutation could then be involved in a mechanism of down regulation of
the ORF1ab proteolytic processing. The vaccine ORF1b has a unique mutation
Y952H in the Nsp10 region of the polyprotein that contains the metal-binding and
helicase domains [18, 24]. Substitution of the aromatic residue Y with a tertiary
amine (H) would change the shape and the change of this region of the putative
protein. Consequently the efficiency of the helicase function could be compro-
mised, which in turn would interfere with the efficiency of virus replication and
then contribute to the acquisition of an attenuation phenotype.
The vaccine RNA pseudoknot stem 1 had a nucleotide change G7687 A when
compared to the pseudoknot stem 1 from other two pathogenic field isolates
(16244B and Iowa). However the vaccine strain was identical to VR-2332 at this
position, which suggests that the change may be not responsible for attenuation of
PRRSV virulence. We did not determine the complete sequence of the vaccine 50
NCR, but we identified one nucleotide substitution over the 165 bases sequenced.
The function of the 50 NCR in PRRSV transcription and replication is not known.
However, it has been reported that the coronavirus 50 NCR is involved in regulatory
functions in the synthesis of subgenomic mRNAs [14]. Although the vaccine
strain was identical to the parental strain at this position we cannot rule out the
possibility that changes in the 50 NCR might alter the efficiency of subgenomic
mRNA transcription in PRRSV.
Together these observed molecular differences in ORF2, ORF3, ORF5, ORF6,
Nsp1b, Nsp2 and Nsp10 and possible conformational changes in the RNA sec-
ondary structure may provide the basis for the attenuated phenotype.
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